Disease-free survival following a dose-intensive weekly regimen of Adriamycin + oral cyclophosphamide augmented with G-CSF support followed by Abraxane and Herceptin 2 years [clinicaltrials_resource:c49fef0f57cd17f7ab2108c0bba76de8]
Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Disease-free survival following a dose-intensive weekly regimen of Adriamycin + oral cyclophosphamide augmented with G-CSF support followed by Abraxane and Herceptin 2 years [clinicaltrials_resource:c49fef0f57cd17f7ab2108c0bba76de8]
Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.
Bio2RDF identifier
c49fef0f57cd17f7ab2108c0bba76de8
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c49fef0f57cd17f7ab2108c0bba76de8
measure [clinicaltrials_vocabulary:measure]
Disease-free survival followin ...... owed by Abraxane and Herceptin
time frame [clinicaltrials_vocabulary:time-frame]
description
Patients receive dose-intensiv ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:c49fef0f57cd17f7ab2108c0bba76de8
title
Disease-free survival followin ...... Abraxane and Herceptin 2 years
@en
type
label
Disease-free survival followin ...... fef0f57cd17f7ab2108c0bba76de8]
@en